Literature DB >> 14567641

Analysis of hepatic disposition of galactosylated cationic liposome/plasmid DNA complexes in perfused rat liver.

Shintaro Fumoto1, Fumi Nakadori, Shigeru Kawakami, Makiya Nishikawa, Fumiyoshi Yamashita, Mitsuru Hashida.   

Abstract

PURPOSE: To determine the intrahepatic disposition characteristics of galactosylated liposome/plasmid DNA (pDNA) complexes in perfused rat liver.
METHODS: Galactosylated liposomes containing N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), cholesterol (Chol), and cholesten-5-yloxy-N-14-[(1-imino-2-D-thiogalactosylethyl)amino]butyl] formamide (Gal-C4-Chol) were prepared. The liposome/[32P]-labeled pDNA complexes were administered to perfused liver, and the venous outflow patterns were analyzed based on a two-compartment dispersion model.
RESULTS: The single-pass hepatic extraction of pDNA complexed with DOTMA/Chol/Gal-C4-Chol liposomes was greater than that with control DOTMA/Chol liposomes. A two-compartment dispersion model revealed that both the tissue binding and cellular internalization rate were higher for the DOTMA/Chol/Gal-C4-Chol liposome complexes compared with the control liposome complexes. The tissue binding was significantly reduced by the presence of 20 mM galactose. When their cellular localization in the perfused liver at 30 min postinjection was investigated, it was found that the parenchymal uptake of the DOTMA/Chol/Gal-C4-Chol liposome complexes was greater than that of the control liposome complexes. The parenchymal cell/ nonparenchymal cell uptake ratio was as high as unity.
CONCLUSION: Galactosylation of the liposome/pDNA complexes increases the tissue binding and internalization rate via an asialoglycoprotein receptor-mediated process. Because of the large particle size of the complexes (approximately 150 nm), however, penetration across the fenestrated sinusoidal endothelium appears to be limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567641     DOI: 10.1023/a:1025766429175

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration.

Authors:  Y K Song; F Liu; S Chu; D Liu
Journal:  Hum Gene Ther       Date:  1997-09-01       Impact factor: 5.695

2.  Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine).

Authors:  M Hashida; S Takemura; M Nishikawa; Y Takakura
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

3.  Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits.

Authors:  J R Chowdhury; M Grossman; S Gupta; N R Chowdhury; J R Baker; J M Wilson
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

4.  Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA.

Authors:  J P Yang; L Huang
Journal:  Gene Ther       Date:  1997-09       Impact factor: 5.250

5.  Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid.

Authors:  F Sakurai; T Nishioka; H Saito; T Baba; A Okuda; O Matsumoto; T Taga; F Yamashita; Y Takakura; M Hashida
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

6.  Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse Laplace transform (FILT).

Authors:  Y Yano; K Yamaoka; Y Aoyama; H Tanaka
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

7.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

8.  The preparation and labeling of DTPA-coupled albumin.

Authors:  D J Hnatowich; W W Layne; R L Childs
Journal:  Int J Appl Radiat Isot       Date:  1982-05

9.  Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs.

Authors:  S Kawakami; C Munakata; S Fumoto; F Yamashita; M Hashida
Journal:  J Pharm Sci       Date:  2001-02       Impact factor: 3.534

10.  Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes.

Authors:  R I Mahato; K Kawabata; T Nomura; Y Takakura; M Hashida
Journal:  J Pharm Sci       Date:  1995-11       Impact factor: 3.534

View more
  6 in total

1.  Development and optimization of nanosomal formulations for siRNA delivery to the liver.

Authors:  Anup K Kundu; Partha K Chandra; Sidhartha Hazari; Yashoda V Pramar; Srikanta Dash; Tarun K Mandal
Journal:  Eur J Pharm Biopharm       Date:  2011-11-18       Impact factor: 5.571

2.  Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.

Authors:  Partha K Chandra; Anup K Kundu; Sidhartha Hazari; Sruti Chandra; Lili Bao; Tara Ooms; Gilbert F Morris; Tong Wu; Tarun K Mandal; Srikanta Dash
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

3.  Stability of lyophilized siRNA nanosome formulations.

Authors:  Anup K Kundu; Partha K Chandra; Sidhartha Hazari; Grace Ledet; Yashoda V Pramar; Srikanta Dash; Tarun K Mandal
Journal:  Int J Pharm       Date:  2011-12-06       Impact factor: 5.875

4.  Novel pentablock copolymers for selective gene delivery to cancer cells.

Authors:  Bingqi Zhang; Mathumai Kanapathipillai; Paul Bisso; Surya Mallapragada
Journal:  Pharm Res       Date:  2009-01-14       Impact factor: 4.200

5.  Poly-L-Lysine-Lactobionic Acid-Capped Selenium Nanoparticles for Liver-Targeted Gene Delivery.

Authors:  Shaigan Naidoo; Aliscia Daniels; Saffiya Habib; Moganavelli Singh
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

6.  Three-Dimensional Imaging of the Intracellular Fate of Plasmid DNA and Transgene Expression: ZsGreen1 and Tissue Clearing Method CUBIC Are an Optimal Combination for Multicolor Deep Imaging in Murine Tissues.

Authors:  Shintaro Fumoto; Koyo Nishimura; Koyo Nishida; Shigeru Kawakami
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.